FDA Approval Insights: Tremelimumab Plus Durvalumab and Chemotherapy in NSCLC

Dr Johnson discusses the FDA approval of tremelimumab plus durvalumab and chemotherapy in non–small cell lung cancer, key data from the POSEIDON trial, and the combination’s efficacy and tolerability in various patient populations.